ライフサイエンスコーパス: DMSA

1 DMSA scans were obtained by both pinhole and SPECT techn

2 DMSA was accepted for scar detection and VCUG for reflux

3 etallic ligand-protected cluster, Ag(4)Ni(2)(DMSA)(4) (DMSA = meso-2,3-dimercaptosuccinic acid) was s

4 se of one equivalent of water-soluble Hg(2+)-DMSA complex which leads to a synchronous detoxifying ef

5 gand-protected cluster, Ag(4)Ni(2)(DMSA)(4) (DMSA = meso-2,3-dimercaptosuccinic acid) was synthesized

6 nization (ESI) mass spectrometry to be Ag(7)(DMSA)(4), where DMSA represents meso-2,3-dimercaptosucci

7 99mTc-DMSA late static planar imaging or SPECT is being used f

8 99mTc-DMSA SPECT, spiral CT, and MR imaging appear to be equal

9 njection of a cortical fixation agent, 99mTc-DMSA or 99mTc-GH, and requires effective immobilization

10 enal length measurements determined by 99mTc-DMSA SPECT into management algorithms.

11 enal length measurements determined by 99mTc-DMSA SPECT is similar to that reported previously using

12 ior image quality in the evaluation of 99mTc-DMSA renal SPECT data, with the potential for markedly r

13 obtained 2-3 hours after injection of 99mTc-DMSA.

14 Fifty sequential pediatric patient 99mTc-DMSA SPECT studies of 98 kidneys were retrospectively an

15 d a literature review, we suggest that 99mTc-DMSA scintigraphy be performed early when evaluating gir

16 1-16 y; mean age, 5.4 y) who underwent 99mTc-DMSA SPECT were measured independently by 2 observers.

17 case, such a kidney was detected with 99mTc-DMSA scintigraphy but not by intravenous pyelography.

18 able 99mTc-labelled dimercaptosuccinic acid (DMSA) assay and contrast cystography.

19 lutions of meso-2,3-dimercaptosuccinic acid (DMSA) at increasing concentration (0.025, 0.050, and 0.1

20 (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P < 0.0001) in the

21 trial (n = 780) of dimercaptosuccinic acid (DMSA) chelation therapy found reduced blood lead levels

22 ting agent meso-2,3-dimercaptosuccinic acid (DMSA) for the simultaneous detection and detoxification

23 imaging with 99mTc-dimercaptosuccinic acid (DMSA) has become the imaging test of choice for the diag

24 aging using (99m)Tc-dimercaptosuccinic acid (DMSA) projects are presented as examples.

25 ter delivery, and a dimercaptosuccinic acid (DMSA) radioisotope scan at 3 months was done on those wi

26 renograms, (99m)Tc-dimercaptosuccinic acid (DMSA) renal cortical scans, (99m)Tc-based hepatobiliary

27 Quantitative 99mTc-dimercaptosuccinic acid (DMSA) renal uptake was studied in unilateral reflux-rela

28 f lack of uptake on dimercaptosuccinic acid (DMSA) scans (P < 0.01).

29 had early and late dimercaptosuccinic acid (DMSA) scans to detect acquired focal defects, and their

30 phy, technetium 99m-dimercaptosuccinic acid (DMSA) scintigraphy, contrast material-enhanced computed

31 obtained with 99mTc-dimercaptosuccinic acid (DMSA) SPECT.

32 ad, tibia lead, and dimercaptosuccinic acid (DMSA)-chelatable lead and measures of neurobehavioral an

33 ation with meso-2,3-dimercaptosuccinic acid (DMSA).

34 pared with those of dimercaptosuccinic acid (DMSA).

35 with the results of dimercaptosuccinic acid (DMSA, as used drug).

36 chelating agent 2,3-dimercaptosuccinic acid (DMSA, succimer).

37 ramme data, we describe change in VBLL after DMSA treatment courses in a cohort of 1,156 children </=

38 ound showed no correlation with VUR, and all DMSA scans but one were normal.

39 itionally, the synergistic effect of BVJ and DMSA against Pb-induced neurotoxicity was assessed.

40 BVJ and DMSA combination displayed a synergistic antineurotoxic

41 re considered, MAG3-F(0) was as sensitive as DMSA.

42 footprinting and DNA mobility shift assays (DMSA) using rat liver nuclear extracts identify a number

43 In most patients with fixed defects on both DMSA and MAG3-F(0), follow-up studies showed no resoluti

44 ient decrease in C/EBP alpha, as measured by DMSA, and an increase in beta 2 AR mRNA levels and rate

45 and compared with the results of concurrent DMSA studies.

46 A new drug, DMSA (meso 2,3-dimercaptosuccinic acid) has been approve

47 Of the 30 early DMSA scans (within 2 weeks of function), one child with

48 sociations between clinical events and focal DMSA lesions appearing in grafts were measured.

49 dysfunction and fixed focal defects and, for DMSA, focal defects without parenchymal loss.

50 from 20 mCi MAG3 were lower than those from DMSA (6 mCi) or GH (20 mCi).

51 al uptake persisted, but the elevated global DMSA accumulation seen for group C (with irreversible im

52 al abnormalities in APN as was the 3- to 4-h DMSA routine procedure.

53 heir mutual interdependence for detection in DMSA, and 4) inhibition of expression of HMG proteins by

54 Scars in DMSA were detected in only 16% (44) of 266 kidneys.

55 differential uptake resulted from increased DMSA accumulation (absolute % dose uptake) by the nondis

56 Courses of DMSA of 19 or 28 d duration administered to children wit

57 Impact of DMSA was calculated as end-course VBLL as a percentage o

58 ffects of the BVJ lead to the improvement of DMSA therapy.

59 0.673-0.789, P < 0.01) for the prediction of DMSA defects.

60 so raises questions about the sensitivity of DMSA, considering that only a small percentage of patien

61 ry to the renal tubule that alters uptake of DMSA.

62 e the renal function and are readily seen on DMSA, but not ultrasound scans.

63 eurobehavioral performance than was tibia or DMSA-chelatable lead, mainly in the domains of executive

64 Oral DMSA was a pharmacodynamically effective chelating agent

65 acers, e.g. (67)Ga-citrate and (99m)Tc-penta-DMSA.

66 elonephritis is slightly better than pinhole DMSA scan, the overall accuracy of these two imaging tec

67 and dimercaptosuccinic acid scintigraphies (DMSA) of all patients who underwent voiding cystourethro

68 (99m)Tc-DMSA is filtered bound to alpha1-microglobulin and accum

69 Renal accumulation of (99m)Tc-DMSA is thus critically dependent on megalin/cubilin rec

70 jected intravenously with 0.5 MBq of (99m)Tc-DMSA or (99m)Tc-mercaptoacetyltriglycine (MAG3).

71 /cubilin-mediated endocytosis of the (99m)Tc-DMSA protein complex.

72 ta for 1062 kidneys, with a positive (99m)Tc-DMSA scan prevalence of 36%.

73 ta for 537 children, with a positive (99m)Tc-DMSA scan prevalence of 59% overall, and seven studies w

74 n UTI who had undergone both MCU and (99m)Tc-DMSA scintigraphy, and which also reported both positive

75 1 acquired its standard 300-s static (99m)Tc-DMSA studies as 5-frame dynamic studies in 29 children.

76 eficient mice an increased amount of (99m)Tc-DMSA was excreted in an approximately 27-kDa form, which

77 No renal accumulation of (99m)Tc-DMSA was identified in scintigrams of megalin/cubilin-de

78 abnormalities and relative uptake of (99m)Tc-DMSA were recorded.

79 )Tc-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) accumulates in the kidney cortex and is widely use

80 99m-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) renal scintigraphy in 2 cases of preemptive LKT de

81 )Technetium-dimercaptosuccinic acid ((99m)Tc-DMSA) scintigraphy.

82 ted for renal cortical imaging using (99m)Tc-DMSA, leading to significant reductions in administered

83 The size and identity of (99m)Tc-DMSA-bound proteins in urine were analyzed by fractionat

84 increase in the urinary excretion of (99m)Tc-DMSA.

85 responsible for the renal uptake of (99m)Tc-DMSA.

86 ptake; however, DMPS was more effective than DMSA (P < 0.001).

87 Evidence exists that DMSA is effective in lowering the blood lead concentrati

88 The sensitivity of the DMSA scan for detection of affected kidneys was 92% for

89 t of pyelonephritis were correlated with the DMSA images and renal pathology.

90 ass spectrometry to be Ag(7)(DMSA)(4), where DMSA represents meso-2,3-dimercaptosuccinic acid.

91 urological potential of BVJ (alone, and with DMSA) towards lead-induced neurotoxicity.

92 nous blood lead level (VBLL) associated with DMSA treatment in the largest cohort of children </= 5 y

93 Associations with DMSA-chelatable lead were similar to those for blood lea

94 Treatment with BVJ in combination with DMSA revealed a synergistic effect in the reduction of n

95 ower specificity for MAG3-F(0) compared with DMSA (86%); this finding needs further study, because it

96 Compared with DMSA and when both regional dysfunction and focal defect

97 However, comparisons with DMSA indicated certain disadvantages of MAG3 SPECT.

98 adjusted P = .045) in children treated with DMSA chelation.